Tori Yamamoto, PhD
Scientist
Business Service Ctr
Chancellor/EVC/FAS

Publications (26)

Top publication keywords:
Receptors, Antigen, T-CellMelanoma, ExperimentalDrug Partial AgonismAdoptive Transferfas ReceptorFas Ligand ProteinImmunotherapyAntigens, NeoplasmImmunotherapy, AdoptiveCD8-Positive T-LymphocytesTumor MicroenvironmentNeoplasms, ExperimentalT-LymphocytesGenetic EngineeringPotassium

• Modular pooled discovery of synthetic knockin sequences to program durable cell therapies.
  Cell 2023 Blaeschke F, Chen YY, Apathy R, Daniel B, Chen AY, Chen PA, Sandor K, Zhang W, Li Z, Mowery CT, Yamamoto TN, Nyberg WA, To A, Yu R, Bueno R, Kim MC, Schmidt R, Goodman DB, Feuchtinger T, Eyquem J, …
• Cancer genes disfavoring T cell immunity identified via integrated systems approach.
  Cell reports 2022 Kishton RJ, Patel SJ, Decker AE, Vodnala SK, Cam M, Yamamoto TN, Patel Y, Sukumar M, Yu Z, Ji M, Henning AN, Gurusamy D, Palmer DC, Stefanescu RA, Girvin AT, Lo W, Pasetto A, Malekzadeh P, Deniger DC,…
• An engineered IL-2 partial agonist promotes CD8+ T cell stemness.
  Nature 2021 Mo F, Yu Z, Li P, Oh J, Spolski R, Zhao L, Glassman CR, Yamamoto TN, Chen Y, Golebiowski FM, Hermans D, Majri-Morrison S, Picton LK, Liao W, Ren M, Zhuang X, Mitra S, Lin JX, Gattinoni L, Powell JD, …
• Evaluation of SARS-CoV-2 serology assays reveals a range of test performance.
  Nature biotechnology 2020 Whitman JD, Hiatt J, Mowery CT, Shy BR, Yu R, Yamamoto TN, Rathore U, Goldgof GM, Whitty C, Woo JM, Gallman AE, Miller TE, Levine AG, Nguyen DN, Bapat SP, Balcerek J, Bylsma SA, Lyons AM, Li S, Wong …
• Multi-phenotype CRISPR-Cas9 Screen Identifies p38 Kinase as a Target for Adoptive Immunotherapies.
  Cancer cell 2020 Gurusamy D, Henning AN, Yamamoto TN, Yu Z, Zacharakis N, Krishna S, Kishton RJ, Vodnala SK, Eidizadeh A, Jia L, Kariya CM, Black MA, Eil R, Palmer DC, Pan JH, Sukumar M, Patel SJ, Restifo NP

Show all (21 more) Hide

• Test performance evaluation of SARS-CoV-2 serological assays.
  medRxiv : the preprint server for health sciences 2020 Whitman JD, Hiatt J, Mowery CT, Shy BR, Yu R, Yamamoto TN, Rathore U, Goldgof GM, Whitty C, Woo JM, Gallman AE, Miller TE, Levine AG, Nguyen DN, Bapat SP, Balcerek J, Bylsma SA, Lyons AM, Li S, Wong …
• Developing neoantigen-targeted T cell-based treatments for solid tumors.
  Nature medicine 2019 Yamamoto TN, Kishton RJ, Restifo NP
• Host conditioning with IL-1β improves the antitumor function of adoptively transferred T cells.
  The Journal of experimental medicine 2019 Lee PH, Yamamoto TN, Gurusamy D, Sukumar M, Yu Z, Hu-Li J, Kawabe T, Gangaplara A, Kishton RJ, Henning AN, Vodnala SK, Germain RN, Paul WE, Restifo NP
• Mg2+ regulation of kinase signaling and immune function.
  The Journal of experimental medicine 2019 Kanellopoulou C, George AB, Masutani E, Cannons JL, Ravell JC, Yamamoto TN, Smelkinson MG, Jiang PD, Matsuda-Lennikov M, Reilley J, Handon R, Lee PH, Miller JR, Restifo NP, Zheng L, Schwartzberg PL, …
• T cell stemness and dysfunction in tumors are triggered by a common mechanism.
  Science (New York, N.Y.) 2019 Vodnala SK, Eil R, Kishton RJ, Sukumar M, Yamamoto TN, Ha NH, Lee PH, Shin M, Patel SJ, Yu Z, Palmer DC, Kruhlak MJ, Liu X, Locasale JW, Huang J, Roychoudhuri R, Finkel T, Klebanoff CA, Restifo NP
• T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapy.
  The Journal of clinical investigation 2019 Yamamoto TN, Lee PH, Vodnala SK, Gurusamy D, Kishton RJ, Yu Z, Eidizadeh A, Eil R, Fioravanti J, Gattinoni L, Kochenderfer JN, Fry TJ, Aksoy BA, Hammerbacher JE, Cruz AC, Siegel RM, Restifo NP, …
• Inhibition of AKT signaling uncouples T cell differentiation from expansion for receptor-engineered adoptive immunotherapy.
  JCI insight 2017 Klebanoff CA, Crompton JG, Leonardi AJ, Yamamoto TN, Chandran SS, Eil RL, Sukumar M, Vodnala SK, Hu J, Ji Y, Clever D, Black MA, Gurusamy D, Kruhlak MJ, Jin P, Stroncek DF, Gattinoni L, Feldman SA, …
• Identification of essential genes for cancer immunotherapy.
  Nature 2017 Patel SJ, Sanjana NE, Kishton RJ, Eidizadeh A, Vodnala SK, Cam M, Gartner JJ, Jia L, Steinberg SM, Yamamoto TN, Merchant AS, Mehta GU, Chichura A, Shalem O, Tran E, Eil R, Sukumar M, Guijarro EP, Day …
• Normalized Synergy Predicts That CD8 Co-Receptor Contribution to T Cell Receptor (TCR) and pMHC Binding Decreases As TCR Affinity Increases in Human Viral-Specific T Cells.
  Frontiers in immunology 2017 Williams CM, Schonnesen AA, Zhang SQ, Ma KY, He C, Yamamoto T, Eckhardt SG, Klebanoff CA, Jiang N
• Fas/CD95 prevents autoimmunity independently of lipid raft localization and efficient apoptosis induction.
  Nature communications 2016 Cruz AC, Ramaswamy M, Ouyang C, Klebanoff CA, Sengupta P, Yamamoto TN, Meylan F, Thomas SK, Richoz N, Eil R, Price S, Casellas R, Rao VK, Lippincott-Schwartz J, Restifo NP, Siegel RM
• Ionic immune suppression within the tumour microenvironment limits T cell effector function.
  Nature 2016 Eil R, Vodnala SK, Clever D, Klebanoff CA, Sukumar M, Pan JH, Palmer DC, Gros A, Yamamoto TN, Patel SJ, Guittard GC, Yu Z, Carbonaro V, Okkenhaug K, Schrump DS, Linehan WM, Roychoudhuri R, Restifo NP
• Memory T cell-driven differentiation of naive cells impairs adoptive immunotherapy.
  The Journal of clinical investigation 2015 Klebanoff CA, Scott CD, Leonardi AJ, Yamamoto TN, Cruz AC, Ouyang C, Ramaswamy M, Roychoudhuri R, Ji Y, Eil RL, Sukumar M, Crompton JG, Palmer DC, Borman ZA, Clever D, Thomas SK, Patel S, Yu Z, …
• Immunotherapy: Treatment of aggressive lymphomas with anti-CD19 CAR T cells.
  Nature reviews. Clinical oncology 2014 Klebanoff CA, Yamamoto TN, Restifo NP
• CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2013 Ye Q, Song DG, Poussin M, Yamamoto T, Best A, Li C, Coukos G, Powell DJ
• Cytomegalovirus-specific T cells are primed early after cord blood transplant but fail to control virus in vivo.
  Blood 2013 McGoldrick SM, Bleakley ME, Guerrero A, Turtle CJ, Yamamoto TN, Pereira SE, Delaney CS, Riddell SR
• Novel serial positive enrichment technology enables clinical multiparameter cell sorting.
  PloS one 2012 Stemberger C, Dreher S, Tschulik C, Piossek C, Bet J, Yamamoto TN, Schiemann M, Neuenhahn M, Martin K, Schlapschy M, Skerra A, Schmidt T, Edinger M, Riddell SR, Germeroth L, Busch DH
• Cross-presentation and genome-wide screening reveal candidate T cells antigens for a herpes simplex virus type 1 vaccine.
  The Journal of clinical investigation 2012 Jing L, Haas J, Chong TM, Bruckner JJ, Dann GC, Dong L, Marshak JO, McClurkan CL, Yamamoto TN, Bailer SM, Laing KJ, Wald A, Verjans GM, Koelle DM
• Generation of CD19-chimeric antigen receptor modified CD8+ T cells derived from virus-specific central memory T cells.
  Blood 2011 Terakura S, Yamamoto TN, Gardner RA, Turtle CJ, Jensen MC, Riddell SR
• Identification of MAGE-C1 (CT-7) epitopes for T-cell therapy of multiple myeloma.
  Cancer immunology, immunotherapy : CII 2011 Anderson LD, Cook DR, Yamamoto TN, Berger C, Maloney DG, Riddell SR
• The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor.
  Blood 2010 Hudecek M, Schmitt TM, Baskar S, Lupo-Stanghellini MT, Nishida T, Yamamoto TN, Bleakley M, Turtle CJ, Chang WC, Greisman HA, Wood B, Maloney DG, Jensen MC, Rader C, Riddell SR
• PIRLs: a novel class of plant intracellular leucine-rich repeat proteins.
  Plant & cell physiology 2005 Forsthoefel NR, Cutler K, Port MD, Yamamoto T, Vernon DM